SCHEMBL2651708

SCHEMBL2651708

Fc1cccc(-c2n[c]c[nH]2)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 2/20 0.40
CCNE2 O96020 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
DCUN1D1 Q96GG9 2/20 0.33
BCAT1 P54687 1/20 0.33
SLC9A1 P19634 1/20 0.33
DHODH Q02127 1/20 0.33
FFAR1 O14842 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
GRIN2B Q13224 1/20 0.32
LRRK2 Q5S007 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
HSD11B1 P28845 1/20 0.32
PDE10A Q9Y233 1/20 0.32
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
PKM P14618 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652138 0.85 DCUN1D1 (0.46) CCNE2CCNE1CDK2DCUN1D1NPC1
SCHEMBL2652004 0.71 AMY1A (0.35) DHODHLRRK2ALDH1A1PIM1PIM3
SCHEMBL1119527 0.70 HSD11B1 (0.41) HSD11B1
SCHEMBL1436578 0.69 CSNK1A1 (0.46) GRK6CCNE2CCNE1CDK2LRRK2
SCHEMBL3038641 0.68 CES2 (0.46) GRK6CCNE2CCNE1CDK2DCUN1D1
SCHEMBL2653389 0.68 CCR1 (0.47) CDK2PDE10ANPC1RAB9AL3MBTL1
SCHEMBL2653870 0.67 ACVR1 (0.44) NPC1ALDH1A1RAB9ACNR2
SCHEMBL2652005 0.66 SMN1; SMN2 (0.38) NPC1ALDH1A1PKMRAB9AMGAM
SCHEMBL5802414 0.66 GRK6 (0.41) GRK6CCNE2CCNE1CDK2DCUN1D1
SCHEMBL2753611 0.66 BCAT1 (0.34) GRK6CCNE2CCNE1CDK2BCAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1635813-A4 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA MERCK & CO INC (US) 2009-07-01 EP disclosed
EP-1534074-A4 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO INC (US) 2008-01-09 EP disclosed
EP-1799241-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY Merck & Co., Inc. (US) 2007-06-27 EP disclosed
WO-2006036770-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO., INC. (US) 2006-04-06 WO disclosed
EP-1635832-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES Merck & Co., Inc. (US) 2006-03-22 EP disclosed
EP-1635813-A2 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA Merck & Co. Inc. (US) 2006-03-22 EP disclosed
EP-1635773-A2 COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION Merck & Co., Inc. (a New Jersey corp.) (US) 2006-03-22 EP disclosed
EP-1534074-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY Merck & Co., Inc. (US) 2005-06-01 EP disclosed
WO-2005000217-A2 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA MERCK & CO., INC. (US) 2005-01-06 WO disclosed
WO-2004110375-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES MERCK & CO., INC. (US) 2004-12-23 WO disclosed
WO-2004110368-A2 COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION MERCK & CO., INC. (US) 2004-12-23 WO disclosed
WO-2004009015-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO., INC. (US) 2004-01-29 WO disclosed